肝细胞癌(肝癌)是临床常见的恶性肿瘤,作者详细回顾了目前肝癌诊疗技术发展过程中面临的实际问题和挑战,并分别从术前治疗方案的预测、术中微创技术的革新、术后疗效的预测与辅助治疗等三个不同方面对肝癌精准外科的研究和临床应用展开...肝细胞癌(肝癌)是临床常见的恶性肿瘤,作者详细回顾了目前肝癌诊疗技术发展过程中面临的实际问题和挑战,并分别从术前治疗方案的预测、术中微创技术的革新、术后疗效的预测与辅助治疗等三个不同方面对肝癌精准外科的研究和临床应用展开了系统阐述。影像学手段和数字智能化技术可以帮助外科医师术前准确评估肝内解剖结构和病灶形态,指导选择相应的治疗方式。腹腔镜微波消融分隔二步肝切除(laparoscopic ablation partition for stagedhepatectomy,LAPS)术等许多不断优化的微创技术极大减少了并发症的发生,且具有出血量少、Ⅰ期术后左肝增大明显、无需引流、患者恢复较快等诸多优势。另外随着创新研究的不断深入,围绕肿瘤异质性和高转移复发特性结合多组学研究分析可以为个体化精准靶向治疗提供新的思路。展开更多
Postoperative hepatic insulin-like growth factor-1(IGF-1)production may be severely disturbed in patients with liver cirrhosis.Complex alterations in the GH/IGF-1 axis are thought to play an important role in the prot...Postoperative hepatic insulin-like growth factor-1(IGF-1)production may be severely disturbed in patients with liver cirrhosis.Complex alterations in the GH/IGF-1 axis are thought to play an important role in the protein catabolism that complicates major surgical procedures.The aim of this study was to explore the effects of parenteral nutrition(PN)with and without growth hormone(GH)on the GH/IGF-1 axis after hepatectomy for hepatocellular carcinoma(HCC)with cirrhosis and evaluate the potential roles of recombinant human GH(rhGH)therapy.Twenty-four patients with HCC with cirrhosis who underwent hepatectomy were randomly divided into two groups:a PN group(n=12)and an rhGH+PN group(n=12).Liver function,serum GH,IGF-1 and IGFBP-3 were measured before the operation and at postoperative days(POD)1 and 6.Insulin-like growth factor-1 and IGFBP-3 mRNA in the liver tissue was detected by RT-PCR.The liver Ki67 immunohistochemistry staining was studied.At the same time,12 patients with cholelithiasis or liver hemangioma who underwent operation served as normal control group.On POD 6,serum prealbumin,GH,IGF-1,IGFBP-3,hepatic IGF-1 mRNA,IGFBP-3 mRNA and liver Ki67 LI were higher in the rhGH+PN group than in the PN group.There was no significant difference in the 6-and 12-month tumor-free survival rate and the median tumor-free survival time between the PN group and the rhGH+PN group(P>0.05).These data indicate that rhGH+PN could ameliorate the changes in the GH/IGF-1 axis after hepatectomy for HCC in the setting of cirrhosis.展开更多
文摘肝细胞癌(肝癌)是临床常见的恶性肿瘤,作者详细回顾了目前肝癌诊疗技术发展过程中面临的实际问题和挑战,并分别从术前治疗方案的预测、术中微创技术的革新、术后疗效的预测与辅助治疗等三个不同方面对肝癌精准外科的研究和临床应用展开了系统阐述。影像学手段和数字智能化技术可以帮助外科医师术前准确评估肝内解剖结构和病灶形态,指导选择相应的治疗方式。腹腔镜微波消融分隔二步肝切除(laparoscopic ablation partition for stagedhepatectomy,LAPS)术等许多不断优化的微创技术极大减少了并发症的发生,且具有出血量少、Ⅰ期术后左肝增大明显、无需引流、患者恢复较快等诸多优势。另外随着创新研究的不断深入,围绕肿瘤异质性和高转移复发特性结合多组学研究分析可以为个体化精准靶向治疗提供新的思路。
文摘Postoperative hepatic insulin-like growth factor-1(IGF-1)production may be severely disturbed in patients with liver cirrhosis.Complex alterations in the GH/IGF-1 axis are thought to play an important role in the protein catabolism that complicates major surgical procedures.The aim of this study was to explore the effects of parenteral nutrition(PN)with and without growth hormone(GH)on the GH/IGF-1 axis after hepatectomy for hepatocellular carcinoma(HCC)with cirrhosis and evaluate the potential roles of recombinant human GH(rhGH)therapy.Twenty-four patients with HCC with cirrhosis who underwent hepatectomy were randomly divided into two groups:a PN group(n=12)and an rhGH+PN group(n=12).Liver function,serum GH,IGF-1 and IGFBP-3 were measured before the operation and at postoperative days(POD)1 and 6.Insulin-like growth factor-1 and IGFBP-3 mRNA in the liver tissue was detected by RT-PCR.The liver Ki67 immunohistochemistry staining was studied.At the same time,12 patients with cholelithiasis or liver hemangioma who underwent operation served as normal control group.On POD 6,serum prealbumin,GH,IGF-1,IGFBP-3,hepatic IGF-1 mRNA,IGFBP-3 mRNA and liver Ki67 LI were higher in the rhGH+PN group than in the PN group.There was no significant difference in the 6-and 12-month tumor-free survival rate and the median tumor-free survival time between the PN group and the rhGH+PN group(P>0.05).These data indicate that rhGH+PN could ameliorate the changes in the GH/IGF-1 axis after hepatectomy for HCC in the setting of cirrhosis.